At long last luvelta-T is shelved, and Sutro seeks a new focus.
ApexOnco Front Page
Recent articles
The Japanese group licenses sapablursen from Ionis for $280m.
First-gen drugs feature in BCL-2 combos, while Jaypirca and BTK degraders apply extra pressure.
The company’s CD38 x CD28 MAb is among recent clinical trial entrants.
Response rates in relapsed NPM1-mutant AML look slightly worse than before, but QTc prolongation could be the real worry.
AbbVie looks to justify its faith in TeneoOne, and Bristol its phase 3 move with BMS-986393.
Genmab quietly reveals pipeline discontinuations and a delay to the son of Darzalex.
Astra squares up to Merck's Curon deal, while Novartis and Galapagos face off in fast-manufactured Car-T.